Document:

Exhibit
10.2

 

Execution
Version

 

AMENDMENT
TO SECURED PROMISSORY NOTE

 

This
Amendment to Secured Promissory Note (this “Amendment”) is made and entered into as of May 10, 2021 (the “Amendment
Effective Date”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “Borrower”), and
1315 Capital II, L.P., a Delaware limited partnership (the “Noteholder”). Capitalized terms used herein but not otherwise
defined shall have the respective meanings given to them in the Note (as defined below).

 

WHEREAS,
the Borrower has entered into that certain Secured Promissory Note dated as of January 7, 2021 (the “Note”), made
in favor of the Noteholder, in the aggregate principal amount of $2,000,000.00 (the “Original Amount”);

 

WHEREAS,
pursuant to Section 12.11 of the Note, any term of the Note may be amended or modified with the written consent of the Borrower and the
Noteholder; and

 

WHEREAS,
the Borrower and Noteholder desire to amend the Note to increase the aggregate principal amount of the Original Amount by $1,000,000.00
(the “Additional Amount”) as further described herein.

 

NOW,
THEREFORE, in accordance with the foregoing and intending to be legally bound hereby, the Borrower and the Noteholder hereby amend
the Note as provided for below, and otherwise further agree as follows:

 

1.Amendment
to the Note. The Note is hereby amended as follows:

 

(a)       The
principal amount as stated on the first page of the Note underneath the heading “Secured Promissory Note” is hereby amended
by (i) deleting the word “$2,000,000.00” and (ii) adding the word “$3,000,000.00” in its place;

 

(b)       The
principal amount as stated in the first clause of the Note is hereby amended by (i) deleting the word “$2,000,000.00” and
(ii) adding the word “$3,000,000.00” in its place;

 

(c)       The
defined term “Loan” is hereby amended by (i) deleting the word “$2,000,000.00” and (ii) adding the word “$3,000,000.00”
in its place;

 

(d)       The
defined term “Pari Passu Note” is hereby amended and restated in its entirety as follows:

 

“Pari
Passu Note” means that certain Secured Promissory Note dated the date hereof, as amended by that certain Amendment to Secured
Promissory Note dated as of May 10, 2021, made by Borrower in favor of the Pari Passu Noteholder in the aggregate principal amount equal
to $4,500,000.00.

 

    	 	 	 

     

    

 

(e)       The
defined term “Security Agreement” is hereby amended and restated in its entirety as follows:

 

“Security
Agreement” means the Security Agreement, dated as of the date hereof, as amended by that certain Amendment to Security Agreement
dated as of May 10, 2021, by and between the Borrower and Noteholder.

 

(f)       Section
5.1 of the Note is hereby amended and restated in its entirety as follows:

 

5.1
Interest Rate.

 

(a)       Except
as otherwise provided herein, (i) the outstanding principal amount of the Original Amount of the Loan made hereunder shall bear interest
at the Applicable Rate commencing January 7, 2021, and (ii) the outstanding principal amount of the Additional Amount of the Loan made
hereunder shall bear interest at the Applicable Rate commencing on the Amendment Effective Date.

 

(b)       Interest
on the outstanding principal amount of the Loan shall accrue in accordance with the terms of Section 5.1(a) until the Loan is paid in
full, whether at maturity, upon acceleration, by prepayment, or otherwise.

 

2.Continued
Effectiveness. Except as amended hereby, the Note shall remain in full force and effect and all of the rights and obligations under
the Note are hereby affirmed. In the event of a conflict between the Note and this Amendment, this Amendment shall control.

 

3.References.
From and after the Amendment Effective Date, any reference to the Note contained in any notice, request, certificate or other instrument,
document or agreement executed concurrently with or after the execution and delivery of this Amendment shall be deemed to include this
Amendment unless the context shall so otherwise require.

 

4.Counterparts.
This Amendment may be signed in two or more counterparts (including by means of telecopied signature pages) any one of which need not
contain the signature of more than one party, but all such counterparts taken together shall constitute one and the same agreement.

 

[remainder
of page intentionally left blank]

 

    	2

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment as of the date first above written.

 

	 	INTERPACE
    BIOSCIENCES, INC.
	 	 	 
	 	By:	/s/
    Thomas W. Burnell
	 	Name:	Thomas
    W. Burnell
	 	Title:	President
    and CEO
	 	 	 
	 	1315 Capital II, L.P.

By: 1315 Capital Management II, LLC, its

general partner

	 	 	 
	 	By: 	/s/
    Adele C. Oliva
	 	Name:	Adele
    C. Oliva
	 	Title:	Managing
    Member

 

[Signature Page to Amendment to Secured Promissory Note]EX-99.5

 Exhibit 10.3 

AMENDMENT TO 
 SECURITY
AGREEMENT 
 This Amendment to Security Agreement (this “Amendment”) is made and entered into as of May 10, 2021
(the “Effective Date”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “Grantor”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership in its capacity as collateral agent
pursuant to the Notes (as hereinafter defined), as secured party (in such capacity, the “Secured Party”). Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Notes. 

WHEREAS, the Secured Party has made a loan to the Grantor in an aggregate unpaid principal amount equal to $3,000,000.00 (the
“Ampersand Loan”), evidenced by that certain Secured Promissory Note dated as of January 7, 2021 (as amended, supplemented or otherwise modified from time to time, the “Ampersand Note”), made by the Grantor and
payable to the order of the Secured Party; 
 WHEREAS, as of the Effective Date, the Secured Party and the Grantor have entered into
that certain Amendment to Secured Promissory Note (the “Ampersand Amendment”) to increase the aggregate principal amount of the Ampersand Loan by $1,500,000.00; 

WHEREAS, 1315 Capital II, L.P., a Delaware limited partnership (“1315 Capital”), has made a loan to the Grantor in an
aggregate unpaid principal amount equal to $2,000,000.00 (the “1315 Loan” and together with the Ampersand Loan, the “Loans”), evidenced by that certain Secured Promissory Note dated as of January 7, 2021 (as
amended, supplemented or otherwise modified from time to time, the “1315 Note” and together with the Ampersand Note, the “Notes”) made by the Grantor and payable to the order of 1315 Capital; 

WHEREAS, as of the Effective Date, 1315 Capital and the Grantor have entered into that certain Amendment to Secured Promissory Note
(the “1315 Capital Amendment”) to increase the aggregate principal amount of the 1315 Capital Loan by $1,000,000.00; 

WHEREAS, the Grantor has entered into that certain Security Agreement dated as of January 7, 2021 (the “Security
Agreement”), made in favor of the Secured Party to secure the payment and performance of the Secured Obligations; 

WHEREAS, pursuant to Section 14 of the Security Agreement, any term of the Security Agreement may be amended or modified with the
written consent of the Grantor and the Secured Party; and 

 WHEREAS, the Grantor and the Secured Party desire to amend the Security Agreement to
reflect the Ampersand Amendment and the 1315 Capital Amendment as further described herein. 
 NOW, THEREFORE, in accordance with the
foregoing and intending to be legally bound hereby, the Grantor and the Secured Party hereby amend the Security Agreement as provided for below, and otherwise further agree as follows: 

1. Amendment to the Security Agreement. The first “WHEREAS” clause of the Security Agreement is hereby amended and restated
in its entirety as follows: 
 WHEREAS, on January 7, 2021, the Secured Party has made a loan to the Grantor (the
“Ampersand Loan”), evidenced by that certain Secured Promissory Note of even date herewith, as amended by that certain Amendment to Secured Promissory dated as of May 10, 2021 (as amended, supplemented or otherwise modified
from time to time, the “Ampersand Note”) in an aggregate unpaid principal amount equal to $4,500,000.00, made by the Grantor and payable to the order of the Secured Party, and 1315 Capital II, L.P., a Delaware limited partnership
(“1315 Capital”) has made a loan to the Grantor (the “1315 Loan” and together with the Ampersand Loan, the “Loans”), evidenced by that certain Secured Promissory Note of even date herewith, as
amended by that certain Amendment to Secured Promissory Note dated as of May 10, 2021 (as amended, supplemented or otherwise modified from time to time, the “1315 Note” and together with the Ampersand Note, the
“Notes”) in an aggregate unpaid principal amount equal to $3,000,000.00, made by the Grantor and payable to the order of 1315 Capital. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to such
terms in the Notes; 
 2. Continued Effectiveness. Except as amended hereby, the Security Agreement shall remain in full force and
effect and all of the rights and obligations under the Security Agreement are hereby affirmed. In the event of a conflict between the Security Agreement and this Amendment, this Amendment shall control. 

3. References. From and after the Effective Date, any reference to the Security Agreement contained in any notice, request, certificate
or other instrument, document or agreement executed concurrently with or after the execution and delivery of this Amendment shall be deemed to include this Amendment unless the context shall so otherwise require. 

 4. Counterparts. This Amendment may be signed in two or more counterparts (including
by means of telecopied signature pages) any one of which need not contain the signature of more than one party, but all such counterparts taken together shall constitute one and the same agreement. 

[remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of
the date first above written. 
  

			
	INTERPACE BIOSCIENCES, INC.

 
			
		
	By	 	 /s/ Thomas W. Burnell

			
	Name: Thomas W. Burnell
	Title: President and CEO

 
			
	
	AMPERSAND 2018 LIMITED
	PARTNERSHIP
		
	By:	 	AMP-18 Management Company Limited

 
			
	
	Partnership, its General Partner
		
	By:	 	AMP-18 MC LLC, its General Partner

 
			
		
	By	 	 /s/ Herbert H. Hooper

			
	Name: Herbert H. Hooper
	Title: Managing Member

  
 [Signature Page to
Amendment to Security Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]